These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32597012)

  • 61. [Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease].
    Filatova EV; Shadrina MI; Karabanov AV; Slominskiĭ PA; Illarioshkin SN; Ivanova-Smolenskaia IA; Limborskaia SA
    Mol Biol (Mosk); 2011; 45(3):459-63. PubMed ID: 21790007
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.
    Giri B; Seamon M; Banerjee A; Chauhan S; Purohit S; Morgan J; Baban B; Wakade C
    Metab Brain Dis; 2022 Aug; 37(6):1687-1696. PubMed ID: 33881722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Imaging in Parkinson's Disease.
    Politis M; Pagano G; Niccolini F
    Int Rev Neurobiol; 2017; 132():233-274. PubMed ID: 28554409
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection.
    Berg D
    J Neural Transm Suppl; 2006; (71):123-32. PubMed ID: 17447423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection.
    Postuma RB; Gagnon JF; Montplaisir J
    J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):1008-13. PubMed ID: 20562452
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The importance of preclinical diagnostics in Parkinson disease.
    Mantri S; Morley JF; Siderowf AD
    Parkinsonism Relat Disord; 2019 Jul; 64():20-28. PubMed ID: 30224266
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Assessment of the progression of Parkinson's disease: a metabolic network approach.
    Eckert T; Tang C; Eidelberg D
    Lancet Neurol; 2007 Oct; 6(10):926-32. PubMed ID: 17884682
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
    Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson's disease.
    Wang J; Yang QX; Sun X; Vesek J; Mosher Z; Vasavada M; Chu J; Kanekar S; Shivkumar V; Venkiteswaran K; Subramanian T
    Parkinsonism Relat Disord; 2015 Jun; 21(6):590-6. PubMed ID: 25825242
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of neuroimaging in Parkinson's disease.
    Bidesi NSR; Vang Andersen I; Windhorst AD; Shalgunov V; Herth MM
    J Neurochem; 2021 Nov; 159(4):660-689. PubMed ID: 34532856
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?
    Kansara S; Trivedi A; Chen S; Jankovic J; Le W
    J Neural Transm (Vienna); 2013 Jan; 120(1):197-210. PubMed ID: 22733089
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transcription Factors: Potential Cell Death Markers in Parkinson's Disease.
    Wang R; Yang S; Nie T; Zhu G; Feng D; Yang Q
    Neurosci Bull; 2017 Oct; 33(5):552-560. PubMed ID: 28791585
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
    Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
    J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Candidate biomarkers for Parkinson's disease.
    Khodadadian A; Hemmati-Dinarvand M; Kalantary-Charvadeh A; Ghobadi A; Mazaheri M
    Biomed Pharmacother; 2018 Aug; 104():699-704. PubMed ID: 29803930
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
    Stern MB; Siderowf A
    Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.